Market news

Myriad Genetics is back in focus after a sharp reset in analyst price targets, with the modelled fair value estimate moving from about US$6.25 to roughly US$3.37, a cut of close to 46%. The shift lines up with more cautious Street commentary that concentrates on execution risk, profitability, and the impact of reduced FY26 guidance on how the stock is valued. As you read on, you will see how to interpret these updates and how to follow the evolving narrative around Myriad Genetics. Stay...

Detailed price information for Mckesson Corp (MCK-N) from The Globe and Mail including charting and trades.

SALT LAKE CITY, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Vishal Sikri has been promoted to Executive Vice President - Commercial, effective September 16, 2026. Vishal has served as the SVP of Product at Myriad for the past year. He has deep understanding of molecular diagnostics and oncology as well as extensive business and commercial leadership experience from his prior roles

Detailed price information for Blink Charging Company (BLNK-Q) from The Globe and Mail including charting and trades.

Myriad Genetics (MYGN) has an average rating of hold and mean price target of $3.37, according to an

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Myriad Genetics (NASDAQ:MYGN) and its peers.

Check out the companies making headlines yesterday:

Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 6.2% in the afternoon session after Piper Sandler double-downgraded the stock to Underweight, stating that major strategic action is likely needed.

Myriad Genetics (NASDAQ:MYGN) shares fell 7. 1% in pre-market trading to $2.

SALT LAKE CITY, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces Myriad management will present at the 21st Annual Wells Fargo Healthcare Conference in Boston on Thursday, September 10, 2026 at 11:00am EST. The presentation will be available through a live audio webcast link in the investor information section of Myriad’s website at investor.myriad.com. About Myriad Genetics Myriad Genetics is

A number of stocks fell in the afternoon session after shares across biotech and big pharma cooled further as traders continued to secure profits following the extraordinary run. The sector had jumped after Phase 3 results for Moderna’s individualized neoantigen mRNA therapy, intismeran, used with Merck’s Keytruda — the first positive late-stage readout for an mRNA-based cancer vaccine over Keytruda alone. With no fresh clinical or regulatory catalyst to extend the advance, the tape has shifted

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 22.3% gain over the past six months, beating the S&P 500 by 11.2 percentage points.

Myriad Genetics (MYGN) is back in focus after its second quarter 2026 earnings missed expectations and the company cut its full year revenue guidance, moves that triggered a sharp selloff in the stock. See our latest analysis for Myriad Genetics. For investors tracking Myriad Genetics over a longer horizon, the recent earnings miss and lower 2026 revenue guidance have accelerated an already weak trend. The 1-day share price return of down 46.74% adds to a year-to-date share price decline of...

Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 46.1% in the afternoon session after the company reported disappointing second-quarter 2026 results that missed Wall Street's expectations and included a reduced full-year forecast.

Detailed price information for Myriad Genetics Inc (MYGN-Q) from The Globe and Mail including charting and trades.

Myriad Genetics (NASDAQ:MYGN) reported second-quarter 2026 revenue of $190.7 million, down 11% from a year earlier, as a 1% decline in total test volume and a 9% decrease in revenue per test weighed on results. The company lowered its full-year revenue and gross-margin outlook and suspended adjusted

Myriad Genetics stock fell after hours after weak Q2 results, lower guidance and an operating loss.

Myriad Genetics faces significant reimbursement headwinds, lowering full-year 2026 revenue guidance to $770-$790 million while advancing key pipeline milestones and strategic initiatives.

Myriad (MYGN) delivered earnings and revenue surprises of -733.33% and -7.12%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Genetic testing company Myriad Genetics (NASDAQ:MYGN) fell short of the market’s revenue expectations in Q2 CY2026, with sales falling 10.5% year on year to $190.7 million. The company’s full-year revenue guidance of $780 million at the midpoint came in 9.7% below analysts’ estimates. Its non-GAAP loss of $0.25 per share was significantly below analysts’ consensus estimates.

Highlights Second quarter 2026 revenue of $190.7 million decreased 11% year-over-year, reflecting a 1% decline in volume and a 9% decrease in average revenue per test year-over-year. The company is engaging payers and executing revenue cycle initiatives expected to improve reimbursement predictability and performance. Maintained strong laboratory operating performance while driving productivity and cost-per-test improvements designed to support industry-leading gross margins. Momentum continues

Detailed price information for Myriad Genetics Inc (MYGN-Q) from The Globe and Mail including charting and trades.

Myriad Genetics partners with AWS to enhance Image Genius, speeding up document processing, and improving insurance workflows for diagnostics.

SALT LAKE CITY, July 23, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its second quarter 2026 earnings conference call at 4:30 pm ET on Thursday, July 30, 2026. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the second quarter of 2026. A live

The only lab test to run four prenatal genetic screens simultaneously as early as eight weeks gestationSALT LAKE CITY, July 21, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces the full commercial launch of FirstGene® Multiple Prenatal Screen, the only lab test that runs four prenatal genetic screens simultaneously from a single blood draw as early as eight weeks gestation.* The FirstGene screen delive

Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid advances in personalized medicine and synthetic biology continue to transform the industry.

Aspira and Myriad Genetics take different approaches to women's health diagnostics, but which stock looks more compelling now? Let's dive in.

Myriad Genetics expands its testing portfolio and advances its Cancer Care Continuum strategy. Can reimbursement risks and cost pressures temper growth?